No evidence that HIV-1 subtype C infection compromises the efficacy of Tenofovir-containing: Cohort study in the United Kingdom

TitleNo evidence that HIV-1 subtype C infection compromises the efficacy of Tenofovir-containing: Cohort study in the United Kingdom
Publication TypeJournal Article
Year of Publication2016
AuthorsWhite E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C, Pillay D, Dunn D, UK HIV Drug Resistance Database, UK Collaborative HIV Cohort Study(UK CHIC)
JournalJ Infect Dis
Date Published2016-05
ISSN0022-1899
Accession Number27732929
Abstract

Concern has been expressed that tenofovir-containing regimens may have reduced effectiveness in the treatment of human immunodeficiency virus type 1 (HIV-1) subtype C infections because of a propensity for these viruses to develop a key tenofovir-associated resistance mutation. We evaluated whether subtype influenced rates of virological failure in a cohort of 8746 patients from the United Kingdom who received a standard tenofovir-containing first-line regimen and were followed for a median of 3.3 years. In unadjusted analyses, the rate of failure was approximately 2-fold higher among patients infected with subtype C virus as compared to those with subtype B virus (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.50-2.31; P < .001). However, the increased risk was greatly attenuated in analyses adjusting for demographic and clinical factors (adjusted HR, 1.14; 95% CI, .83-1.58; P = .41). There were no differences between subtypes C and subtypes non-B and non-C in either univariate or multivariate analysis. These observations imply there is no intrinsic effect of viral subtype on the efficacy of tenofovir-containing regimens.

DOI10.1093/infdis/jiw213